Metronidazole News and Research

RSS
Optimer study highlights economic burden of acute and recurrent CDI in hospital patients

Optimer study highlights economic burden of acute and recurrent CDI in hospital patients

New England Journal publishes fidaxomicin Phase 3 trial results against CDI

New England Journal publishes fidaxomicin Phase 3 trial results against CDI

FDA accepts Optimer's fidaxomicin NDA for filing

FDA accepts Optimer's fidaxomicin NDA for filing

China Sky third quarter total revenue decreases 16.3% to $36.2 million

China Sky third quarter total revenue decreases 16.3% to $36.2 million

Optimer presents two fidaxomicin Phase 3 trials data for CDI infection at IDSA Annual Meeting

Optimer presents two fidaxomicin Phase 3 trials data for CDI infection at IDSA Annual Meeting

Progenics receives NIH grant to develop novel monoclonal antibodies to treat C. difficile infection

Progenics receives NIH grant to develop novel monoclonal antibodies to treat C. difficile infection

Optimer submits fidaxomicin rolling NDA for treatment of Clostridium difficile infection

Optimer submits fidaxomicin rolling NDA for treatment of Clostridium difficile infection

Optimer Pharmaceuticals to present fidaxomicin Phase 3 clinical trial data at ICAAC Conference

Optimer Pharmaceuticals to present fidaxomicin Phase 3 clinical trial data at ICAAC Conference

Progenics Pharmaceuticals presents findings of humanized monoclonal antibodies against C. difficile bacterium

Progenics Pharmaceuticals presents findings of humanized monoclonal antibodies against C. difficile bacterium

Fidaxomicin, CDA1/CDB1 effective for treating CDI : Report

Fidaxomicin, CDA1/CDB1 effective for treating CDI : Report

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Sagent Pharmaceuticals recalls metronidazole injection

Sagent Pharmaceuticals recalls metronidazole injection

Second fidaxomicin Phase 3 clinical study data in patients with CDI to be presented at DDW 2010

Second fidaxomicin Phase 3 clinical study data in patients with CDI to be presented at DDW 2010

Optimer Pharmaceuticals announces results from second Phase 3 clinical study of fidaxomicin

Optimer Pharmaceuticals announces results from second Phase 3 clinical study of fidaxomicin

Proper diagnosis, treatment and good skin care help control acne and rosacea

Proper diagnosis, treatment and good skin care help control acne and rosacea

FDA grants approval for Abbott's antiretroviral medication Norvir

FDA grants approval for Abbott's antiretroviral medication Norvir

Top-line results from Optimer Pharmaceuticals' second fidaxomicin Phase 3 trial in CDI patients

Top-line results from Optimer Pharmaceuticals' second fidaxomicin Phase 3 trial in CDI patients

Men who buy fake internet drugs for ED problems face significant health risks

Men who buy fake internet drugs for ED problems face significant health risks

Over 44% of internet Viagra is counterfeit

Over 44% of internet Viagra is counterfeit